vimarsana.com

Latest Breaking News On - Source sk biopharmaceuticals co ltd - Page 1 : vimarsana.com

SK Biopharmaceuticals Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SK Biopharmaceuticals Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference

SK Biopharmaceuticals Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPEDtm Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference

SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, today announced.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.